NCT03294707View on ClinicalTrials.gov

Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 11, 2017

Primary Completion Date

February 5, 2018

Study Completion Date

May 18, 2018

Conditions
Amyloid Cardiomyopathy, Transthyretin-Related
Interventions
DRUG

AG10 oral tablet

Active single ascending dose

DRUG

Placebo Oral Tablet

Placebo single dose

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Eidos Therapeutics, a BridgeBio company

INDUSTRY

NCT03294707 - Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10 | Biotech Hunter | Biotech Hunter